MagnetisMM-4
Phase 1/2 Clinical Trial Evaluating the Safety, Effectiveness and Best Dose of Elranatamab Combined with Different Anti-Cancer Therapies in Participants with Multiple Myeloma
What will happen during the trial?
This clinical trial is being conducted in several different sub-studies. This trial is open-label, which means that participants and the study team will know which part participants are enrolled in, and which drugs / doses they will be receiving. One sub-study is currently open and enrolling participants.
Sub-Study A: Elranatamab and Nirogacestat
Phase 1b will give different doses of Elranatamab combined with Nirogacestat to participants to evaluate which dose is the safest and works best.
Phase 2 will give the give the best dose of Elranatamab combined with Nirogacestat (determined by Phase 1) to more participants to learn more about it’s safety, efficacy and how it works in the body.
After the end of the study, researchers may ask you to have monthly follow up visits, or telephone calls with the study team every few months.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 120 patients (estimated)
- Sponsors
- Pfizer
- Tags
- Bispecific Antibody, Gamma-Secretase Inhibitor, B-Cell Maturation Antigen (BCMA), CD3
- Trial Type
- Treatment
- Last Update
- 2 weeks ago
- SparkCures ID
- 1222
- NCT Identifier
- NCT05090566
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.